-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Continuous Launch of New Active Pharmaceutical Ingredients! Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Receives Approval for Finafene Active Pharmaceutical Ingredient
Category:
发布时间：2025-12-05
【概要描述】
On December 5, finerenone, developed by Hebei Guolong Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. This marks the second such approval in China. To date, the Group holds 91 API varieties, 42 of which are manufactured by Guolong Pharmaceutical.
On December 5, finerenone, developed by Hebei Guolong Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. This marks the second such approval in China. To date, the Group holds 91 API varieties, 42 of which are under Guolong Pharmaceutical.
According to available information, finerenone is a mineralocorticoid receptor antagonist; its formulation is indicated for adult patients with chronic kidney disease associated with type 2 diabetes who also have albuminuria, to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular death, and hospitalization for heart failure.
In recent years, the Group has positioned itself in both domestic and international markets, continuously advancing the high-end development of injectable formulations, the diversification of oral dosage forms, and the specialized development of active pharmaceutical ingredients. As a result, it has gradually established an integrated “API-plus-formulation” product chain spanning areas such as anti-infectives, antivirals, respiratory diseases, neurological disorders, nephrology, cardiovascular and cerebrovascular diseases, gastroenterology, anesthesia, and endocrinology. Leveraging process optimization and digital transformation, the Group has consistently strengthened its quality and cost advantages, becoming a reliable partner for numerous formulation manufacturers and providing sustained momentum for the efficient translation of corporate innovation into commercial success.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091